Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Sutent as second-line treatment for pleural mesothelioma
ISRCTN03334163Phase 2Completed
- Sponsor
- Sir Charles Gairdner Hospital
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in pleural mesothelioma, sponsored by Sir Charles Gairdner Hospital. Primary endpoint: Objective response rate. Started Jun 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ISRCTN03334163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN03334163.